Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on February 6, 2024, covering events that occurred on February 1, 2024. The filing details a significant change in corporate control, a new debt obligation, and an extension of the deadline for a proposed merger with Serina Therapeutics, Inc.
Key Financial Metrics and Capital Structure
- Debt Obligation: AgeX drew $500,000 under its Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited. The principal balance is due and payable on February 14, 2024.
- Equity Issuance: AgeX issued 29,388,888 shares of common stock to JuvVentures (UK) Limited (a subsidiary of Juvenescence) via the automatic conversion of Series A and Series B Preferred Stock.
- Ownership Structure: Following the conversion, Juvenescence holds 66,447,499 shares, representing 75.6% of the issued and outstanding common stock as of February 1, 2024.
- Liquidity and Margins: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins.
Material Changes Versus Prior Period
- Change in Control: Juvenescence now holds a majority voting interest (75.6%), granting it the power to elect all board members and approve stockholder matters. This qualifies AgeX as a "controlled company" under NYSE American rules, potentially exempting it from certain independence requirements for the Board and committees (except the Audit Committee).
- Merger Timeline: The "End Date" for the proposed merger with Serina Therapeutics, Inc. was extended by 60 calendar days from February 29, 2024, to April 29, 2024.
Guidance, Outlook, and Risks
Merger Outlook: Upon consummation of the merger, Serina equity holders are expected to own approximately 75% of the combined company, while pre-merger AgeX holders will own approximately 25% (on a pro forma fully diluted basis). This assumes a closing stock price of at least $12.00 per share (post-reverse split). Juvenescence has entered a support agreement to vote in favor of the merger.
Risks and Contingencies:
- Failure of stockholders to approve the merger or failure to satisfy closing conditions.
- Risks associated with Serina's preclinical and clinical programs, including regulatory approvals and commercialization.
- Potential dilution of existing shareholders due to the issuance of shares to Serina holders and the exercise of warrants.
- Uncertainty regarding the combined company's ability to secure sufficient financing to fund operations.
- Operational distractions and costs associated with the merger process.
Investor Verification Checklist
- Verify the repayment status of the $500,000 Secured Note due February 14, 2024.
- Review the preliminary proxy statement/prospectus (Form S-4/S-1) for detailed terms of the merger with Serina Therapeutics.
- Confirm the final pro forma ownership percentages and the impact of the proposed reverse stock split.
- Assess the combined company's projected cash runway and financing needs post-merger.
- Monitor the status of the special stockholder meeting required to approve the merger and related stockholder matters.